Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma. Issue 6 (November 2015)

• Record Type: Journal Article
• Authors: Liu, Meng; Cui, Lian-Hua; Li, Cheng-Cheng; Zhang, Li
• Is Part Of: European journal of cancer prevention. Volume 24:Issue 6(2015:Nov.)
• Publication Date: 2015-11
• Subjects: Cancer -- Prevention -- Periodicals; Neoplasms -- etiology -- Periodicals; Neoplasms -- prevention & control -- Periodicals; Cancer -- Prevention; Periodicals; 616.994052
• DOI: 10.1097/CEJ.0000000000000121
• Languages: English
• ISSNs: 0959-8278

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>Studies of the relationships of adenomatous polyposis coli (<italic>APC</italic>), glutathione-<italic>S</italic>-transferase P1 (<italic>GSTP1</italic>) and suppressor of the cytokine signalling 1 (<italic>SOCS1</italic>) promoter region methylation with the risk of hepatocellular carcinoma (HCC) have yielded inconsistent results. We carried out the current meta-analysis to comprehensively assess the associations between <italic>APC</italic>, <italic>GSTP1</italic> and <italic>SOCS1</italic> promoter methylation frequency and the risk of HCC. All relevant reports were identified by searching the PubMed, Embase, Web of Science, CNKI and the Chinese BioMedical Literature databases before 1 March 2014, with restriction to articles published in the Chinese and English languages. Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated to investigate the rates of <italic>APC</italic>, <italic>GSTP1</italic> and <italic>SOCS1</italic> promoter methylation and the risk of HCC. Our meta-analysis identified relationships of <italic>APC</italic> (12 studies with 592 HCC tumour tissues), <italic>GSTP1</italic> (14 studies including 646 HCC tumour tissues) and <italic>SOCS1</italic> (11 studies with 512 HCC tumour tissues) promoter methylation with the risk of HCC. Compared with paracancerous tissues, the pooled ORs of <italic>APC, GSTP1</italic> and <italic>SOCS1</italic> promoter region methylation in HCC cancer tissues were 5.32 (95% CI=2.96–9.56), 5.65, (95% CI=3.41–9.35) and 2.73 (95% CI=1.37–5.44), respectively. Compared with normal liver tissues as controls, the pooled ORs of <italic>APC</italic>, <italic>GSTP1</italic> and <italic>SOCS1</italic> promoter region methylation in HCC cancer tissues were 20.43 (95% CI=5.56–75.08), 18.78 (95% CI=5.76–61.19) and 13.00 (95% CI=5.20–32.47), respectively. Subgroup analysis by ethnicity showed that <italic>APC</italic>, <italic>GSTP1</italic> and <italic>SOCS1</italic> promoter methylation was associated significantly with the risk of HCC in both Asian and White populations (all <italic>P</italic><0.05). Our meta-analysis suggested strong associations between <italic>APC</italic>, <italic>GSTP1</italic> and <italic>SOCS1</italic> gene promoter methylation and the risk of HCC, suggesting these to be promising biomarkers for HCC.</p> </sec> </abstract>